Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection

Vemlidy® is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade

Published
12 January 2017
From
Gilead press release
U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

Published
11 November 2016
From
Gilead press release
HCV Drugs May Reactivate HBV, FDA Warns

Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

Published
06 October 2016
From
Medscape (free registration required)
ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it has taken a major step forward in its pursuit of a potentially curative combination therapy for chronic hepatitis B (HBV).

Published
12 September 2016
From
ContraVir press release
Act now for a Hepatitis-free Indonesia

In the archipelago, hepatitis B is a virus that affects around 28 million people, or roughly around 10 percent of the population, with 14 million people at risk of the virus developing into chronic cirrhosis or liver failure.

Published
07 September 2016
From
Jakarta Post
High cost hampers treatment of hepatitis B, C in Vietnam: experts

A course of treatment for the diseases costs up to VND45 million (US$2,016), according to Nguyen Van Kinh, director of the National Hospital for Tropical Diseases.

Published
31 August 2016
From
Thanh Nien Daily
'Screen-and-treat' scheme for hepatitis B may prevent deadly complications

Research into Africa's first 'screen-and-treat' programme for hepatitis B suggests the initiative may reduce deadly complications of the virus. The new findings, from researchers at a number of international institutions including Imperial College London and the Medical Research Council Unit The Gambia, also suggest the initiative is feasible and cost-effective.

Published
27 July 2016
From
Eurekalert Inf Dis
Complete clearance of hepatitis B is rare - especially in women and people of Asian descent

Researchers at several different US sites have found that less than one-third of 1% of patients infected with hepatitis B virus (HBV) get rid of the virus per year, and overall, only 1.2% of patients finally get rid of it.

Published
12 July 2016
From
Eurekalert Inf Dis
Interferon-based therapy improves clinical outcomes in hepatitis delta infection

Patients with hepatitis delta virus infection treated with pegylated interferon alpha were less likely to develop clinical outcomes — like decompensation or hepatocellular carcinoma — compared with patients who received nucleos(t)ide based treatment or no treatment at all, according to a presentation at International Liver Congress.

Published
22 April 2016
From
Healio
ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study

Viral rebound studies showed that CMX157 demonstrates best-in-class duration of activity. Nine days following incubation with HBV, using two different experimental conditions, one at equimolar and one at EC90 concentrations, CMX157 showed two- to three-fold reduced viral rebound compared to TAF.

Published
30 March 2016
From
ContraVir press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.